Novo Nordisk's Irish Plant Buildout and Indian Growth Bet Offset FDA Setback

Novo Nordisk is pressing ahead on three fronts at once — expanding manufacturing, deepening its presence in emerging markets, and returning capital to shareholders — even as a regulatory snag in the United States and a cautious Wall Street note keep sentiment in check.

The Danish drugmaker's buyback machine has already chewed through a substantial slice of its budget. According to company figures released Monday, Novo Nordisk had repurchased 37,849,179 B-shares as of October 9, at a total transaction value of DKK 10,558,876,422. The program, launched on February 4, 2026, runs for twelve months and carries a ceiling of up to DKK 15 billion.

432 Million Euro Injection at Athlone

Alongside those capital measures, the company is widening its industrial footprint. Media reports point to extensive construction and engineering work underway at its Athlone site, where EUR 432 million is being committed primarily to boost manufacturing capacity for oral GLP-1 treatments. Commercial production at the Irish facility is slated to resume in stages starting late 2027 and continuing through 2028. Industry observers view such in-house capacity expansion as a critical building block for meeting the long-term demand for GLP-1 therapies.

Denecimig Review Stalls in Washington

Stateside, Novo Nordisk faces a longer wait on a key pipeline candidate. The FDA has extended its review of Denecimig, a treatment for hemophilia A, citing remediation work at a production facility. No new formal decision date was provided. The company stressed that no deficiencies were found in the clinical efficacy or safety data, and that the delay carries no impact on its full-year 2026 financial outlook. Subject to approval, Novo Nordisk now targets a U.S. launch of Denecimig in the first half of 2027.

India Chief Eyes 15–20% Annual Growth

Investor attention has also been drawn to South Asia, where Novo Nordisk's India managing director reportedly projected annual growth of 15% to 20% for the country's GLP-1 market. The launch of an obesity pill is planned for around mid-2027, pending regulatory clearance. India's large population and rising prevalence of metabolic diseases make it a strategically vital market, and an oral therapy format could open the door to patient groups beyond the company's traditional Western strongholds.

BMO Trims Target, Cites Ozempic Headwinds

Not everything is working in the company's favor. Analyst Evan Seigerman of BMO Capital lowered his price target on Novo Nordisk from $47 to $40 on Monday, keeping a Market Perform rating. He pointed to a demanding comparison base and eroding U.S. market share that could weigh on Ozempic's revenue potential.

The stock closed yesterday at EUR 34.99, up 2.6%, a move the company did not attribute to any specific corporate development. Today the shares are trading at EUR 34.88, a modest daily decline of 0.3%. Year-to-date, the equity is down 21%.

Novo Nordisk is countering these market swings with sustained investment in its pipeline, manufacturing base, and its own shares.